Results 301 to 310 of about 1,853,159 (330)
Some of the next articles are maybe not open access.

Preclinical Evaluation of CD36-Targeting Antiangiogenic Peptide ABT-510 for Near-Infrared Fluorescence Molecular Imaging of Colorectal Cancer.

Analytical Chemistry, 2023
Surgical resection constitutes the first choice of treatment for colorectal cancer (CRC). Despite advancements in intraoperative navigation, there remains a considerable lack of effective targeting probes for the imaging-guided surgical navigation of CRC
Ping Luo   +6 more
semanticscholar   +1 more source

Analysis of Complications in Sacroiliac Joint Fusions Using FDA 510(k) Cleared Devices

Clinical Spine Surgery, 2021
Study Design: This was a level III—retrospective cohort study. Objective: The objective of this study was to present an unbiased report of the current rate of severe complications for Federal Drug Administration (FDA) 510(k) cleared sacroiliac joint (SIJ)
Michael D. Rahl   +2 more
semanticscholar   +1 more source

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.

Journal of Clinical Oncology, 2019
3003 Background: The KRASG12C mutation is found in approximately 13% of lung adenocarcinomas and 1–3% of other solid tumors, but there is no approved therapy that targets this mutation. AMG 510 is a novel small molecule that specifically and irreversibly
M. Fakih   +11 more
semanticscholar   +1 more source

CircRNA SCARB1 promotes renal cell carcinoma progression via miR-510-5p/SDC3 axis.

Current Cancer Drug Targets, 2020
BACKGROUND Emerging studies have indicated that circular RNAs (circRNAs) play important roles in the development of many tumors. CircRNA-scavenger receptor class B member 1 (Circ-SCARB1) was consistently reported as an elevated circRNA in RCC tissues ...
Jijian Sun, Shijie Pan, Hong Cui, Hao Li
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy